New late-stage trial data show Regeneron and Roche’s antibody cocktail against COVID-19 cut hospitalization or death by 70% versus a placebo in non-hospitalised patients, the Swiss drugmaker said on Tuesday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,